Sionna Therapeutics, Inc. SION

SION Company Overview

Sionna Therapeutics, Inc. (NASDAQ: SION) is a clinical-stage biotechnology company focused on developing therapies for cystic fibrosis (CF). The company’s research strategy is centered on restoring the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein through a portfolio of small-molecule modulators designed to stabilize and correct CFTR defects. Sionna operates within the biotechnology and rare disease therapeutics industries, with its primary commercial focus directed toward patients with CF mutations that are insufficiently addressed by currently available therapies. Its core revenue model remains development-stage and is therefore dependent on research financing, strategic partnerships, and capital markets activity rather than product commercialization.

Sionna was formed through the integration of scientific programs and intellectual property related to CFTR modulation and protein stabilization technologies. The company has emphasized differentiated approaches targeting the nucleotide-binding domain 1 (NBD1) region of the CFTR protein, an area viewed as important for correcting the underlying protein-folding defects associated with CF. Public disclosures indicate that the company has sought to position itself as a next-generation CF therapeutic developer capable of complementing or improving upon existing modulator regimens in the market.